







Whole genome and transcriptome-assisted immune profiling of metastatic tumours: a precision medicine approach to immunotherapy trial design

Zakhar Krekhno, PhD

Canada's Michael Smith

Genome Sciences Centre at BC Cancer

Vancouver, BC, Canada




Disclosure Information



CAPTIV-8 is an investigator-initiated study from BC Cancer, Vancouver that is partially funded by Roche Canada

Personalized OncoGenomics (POG)



- **Whole genomes and transcriptomes (WGTA)** short read sequencing from **1668 adult** cases and **179 pediatric** cases
- Research results are discussed at a molecular tumour board
- **Clinically actionable** findings are identified in 83% of cases
- **WGTA-informed therapies** are administered in 37% of cases
- **Patients show clinical benefit** in 46% of treated cases




3

Whole genome and transcriptome-assisted immune profiling of metastatic tumours: a precision medicine approach to immunotherapy trial design
 Pleasance, Bohm *et al.*, *Annals of Oncology*, 2022
 Pleasance, Titmuss, Williamson *et al.*, *Nature Cancer*, 2020

POG Pipeline and Reporting




POG Patients Treated with Immune Therapy




ICI received	n (%)
PD-1	45 (55)
PD-L1	10 (12)
PD-1/IDO1	8 (10)
PD-L1/CTLA-4	8 (10)
NKG2A	2 (2)
CTLA-4	1 (1)
PD-L1/OX40	1 (1)
PD-1/CTLA-4	1 (1)
OX40	1 (1)
PD-1/Chemo	1 (1)
PD-1/LAG-3	1 (1)
PD-L1/CTLA-4/Chemo	1 (1)
PD-L1/HER2	1 (1)
PD-L1/SMAC	1 (1)


Combinations of Markers are Effective





19	13	6	0	0	0
63	31	11	5	2	1



33	20	9	3	2	1
32	10	2	0	0	0





33	20	9	3	2	1
32	10	2	0	0	0



6	2	1	0	0
23	6	4	1	0
14	0	0	0	0
22	1	0	0	0

CAPTIV-8 (NCT04273061)

- CAPTIV-8 is an investigator-initiated study from BC Cancer, Vancouver that is partially funded by Roche Canada
- Open label, phase 2 study matching Canadian subjects, who have undergone whole genome and transcriptome analysis (WGTA).
- To date, 31 patients have been enrolled with a target of 50 participants total by April 2026



Summary

- By integrating multiple alteration classes, WGTA can broaden the number of molecularly informed therapies
- Retrospective analysis of immune therapy treated patients revealed integration of multiple biomarkers improved prediction of therapeutic response
- CAPTIV-8 will determine if the information from WGTA-derived biomarkers corresponds with response to atezolizumab

Acknowledgements



POG PIs:

Marco Marra
Janessa Laskin

This work would not be possible without the participation of our patients and families, the POG team, the GSC platform, and the generous support of the BC Cancer Foundation, Genome British Columbia, the Terry Fox Research Institute Marathon of Hope Cancer Centres Network, and Roche Canada.

personalizedoncogenomics.org
POG team

https://www.cbioportal.org/study/summary?id=pog570_bcgsc_2020
Searchable POG data for POG570 cohort

zkrehno@bcgsc.ca